News
Public · Published
Amgen Stocks Move Lower Before Tonight's Earnings Report
Amgen shares were at $464.54, down 0.19% as of 11:19 a.m. ET on November 3, ahead of third-quarter results due after the closing bell, followed by a 4:30 p.m. ET management call. Consensus estimates were $9.95 billion in revenue and $5.74 in earnings per share.
Published:
Updated:
What happened
Amgen shares were at $464.54, down 0.19% as of 11:19 a.m. ET on November 3, ahead of third-quarter results due after the closing bell, followed by a 4:30 p.m. ET management call. Consensus estimates were $9.95 billion in revenue and $5.74 in earnings per share.
Confirmed
Global impact / market context
The estimates imply revenue falls about 1.5% and earnings per share about 8.7% from the second quarter, so earnings drop faster than sales. That gap points to pressure on profit per sale or higher spending, which investors will weigh against the full-year outlook.
Analyst inference
The article's price-to-earnings ratio suggests investors already pay a high price for each dollar of Amgen profit. Its GF Score leans on profitability and growth over financial strength and momentum, so a weak earnings report could pressure the shares.
Analyst inference
What to watch
- Watch whether reported third-quarter revenue and earnings per share clear the $9.95 billion and $5.74 consensus figures, and how they compare with the roughly $10.1 billion and $6.29 reported for the second quarter. Confirmed
- Listen for whether product mix and the timing of expenses explain the sharper earnings drop, since those factors would show whether the decline is temporary or signals weaker profit per sale. Analyst inference
- Track any update to the August full-year outlook of $38.2 billion to $39.4 billion in revenue and $22.30 to $23.50 in non-GAAP earnings per share. Proposed